Establishes provisions relating to the coverage of prescription insulin drugs under certain policies of health insurance. (BDR 57-1167)

AB 555 caps out-of-pocket costs for prescription insulin under private health insurance policies at $35 for a 30-day supply, directly affecting insured individuals with diabetes (including type I, II, and gestational diabetes). It prohibits insurers from charging more than this amount regardless of the specific insulin drug prescribed, while requiring coverage to align with standard policy terms for other treatments. The bill excludes coverage for Medicaid/CHIP recipients and government employees (including their dependents), and allows the Insurance Commissioner to penalize non-compliant insurers. This policy change takes effect immediately without additional state or local costs.